Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
This RT-PCR diagnostic kit helps in diagnosis of AS by detecting HLAB27 gene
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Partnership with Modality, award-winning GP super partnership
The funding round is led by Kalaari Capital. Aflac Ventures, Digital Horizon, Stride Ventures, and existing investors also participated in the round
There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution
Phablecare closed this acquisition for an undisclosed sum, betting on the start-up's holistic approach to Type 1 Diabetes management
As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials
Subscribe To Our Newsletter & Stay Updated
